吡柔比星与丝裂霉素在浅表性膀胱癌术后治疗的应用价值研究

Pirarubicin and Mitomycin in the Superficial Bladder Cancer Hae Applied Value of Postoperative Therapy

目的:探讨吡柔比星联合丝裂霉素在浅表性膀胱癌术后膀胱灌注治疗中的应用价值。方法:回顾性分析我院2007年4月-2011年4月术后采用吡柔比星与丝裂霉素交替灌注治疗的68例膀胱癌患者的临床资料,并以同期单纯采用丝裂霉素进行术后灌注治疗的68例膀胱癌患者为对照组。结果:观察组术后复发率明显低于对照组,组间比较差异具有统计学意义(P<0.05)。治疗期间观察组患者不良反应发生率低于对照组,组间比较差异具有统计学意义(P<0.05)。结论:采用吡柔比星与丝裂霉素进行交替膀胱灌注治疗可有效降低浅表性膀胱癌术后复发率。

Objective：Pirarubicin and mitomycin in superficial bladder cancer hae crack of postoperative therapy applied value,improve the efficiency of the clinical treatment of superficial bladder cancer.Methods：A retrospective study was April 2007 to April 2011 using pirarubicin after mitomycin of fosomycin alternate reperfusion in 68 patients with bladder cancer patients with clinical information,and using the same simple of fosomycin receied reperfusion in 68 patients with bladder cancer patients（control group）,compared with therapeutic effect of two groups.Results：The observation group＇s postoperative recurrence was obviously lower than the control group which had statistically significant comparative differences（P0.05）.During treatment,the observation group patients group was lower incidence of adverse reactions between groups.It had statistically significant comparative differences（P0.05）.Conclusion：Pirarubicin and mitomycin treating bladder cancer can effectively reduce the recurrence rate and improve their patients who underwent the quality of life.